Clinical review report : indication : a complete regimen for the treatment of HIV-1 infection in adults with no known substitution associated with resistance to the individual components of Biktarvy. Bictegravir/Emtricitabine/Tenofovir alafenamide (B/FTC/TAF) (Biktarvy) (Gilead Sciences Canada, Inc.) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Outcome assessment (Medical care).

Highly active antiretroviral therapy.

Physical Description:

1 online resource (90 pages) : illustrations

Place of Publication:

Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2018.

Summary:

The objective of this systematic review was to evaluate the efficacy and safety of the fixed-dose combination (FDC) bictegravir/emtricitabine/tenofovir alafenamide (B/FTC/TAF) 50 mg/200 mg/25 mg, once daily, as a treatment for HIV type 1 (HIV-1) infection in adults with no known substitution associated with resistance to the individual components of B/FTC/TAF. Of which, B is an integrase strand transfer inhibitor, and both emtricitabine (FTC) and tenofovir alafenamide (TAF) are nucleoside reverse transcriptase inhibitors.

Notes:

Description based on publisher supplied metadata and other sources.